nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.02.2013 | Original Paper

Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy

verfasst von: Vesna Bišof, Antonija Jakovčević, Sven Seiwerth, Zoran Rakušić, Slavko Gašparov

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the prognostic significance of excision repair cross-complementation group 1 (ERCC1) expression in head and neck carcinoma patients treated with definitive radiotherapy (DR) or adjuvant radiotherapy (AR).

Methods

ERCC1 expression was assessed by immunohistochemical staining. A total of 48 patients were assessed.

Results

High ERCC1 expression was found in 23 patients (48 %). More ERCC1-positive tumours were detected in patients treated with DR than in patients treated with AR (73 vs. 36 %, respectively, p = 0.03). ERCC1 expression had no impact on overall survival neither in the whole cohort of patients (p = 0.16) nor in each particular treatment group (AR p = 0.98; DR p = 0.21).

Conclusions

ERCC1 expression had no predictive value in head and neck carcinoma patients treated with DR or AR. There might be difference in ERCC1 positivity that comes out of whether the assessment is done on biopsy or surgical specimens.

Ahmad A, Robinson AR, Duensing A, van Drunen E, Berna Beverloo H, Weisberg H, Hasty P, Hoeijmakers JHJ, Niedernhofer LJ (2008) ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol 28:5082–5092PubMedCrossRef

Bergstralh DT, Sekelsky J (2008) Interstrand crosslink repair: can XPF-ERCC1 be let off the hook? Trends Genet 24:70–76PubMedCrossRef

Carles J, Monzo M, Amat M, Jansa S, Artells R, Navarro A, Foro P, Alameda F, Gayete A, Gel B, Miguel M, Albanell J, Fabregat X (2006) Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with stage I to II head and neck cancer. Int J Radiat Oncol Biol Phys 66:1022–1030PubMedCrossRef

De Castro G, Jr Pasini FS, Siqueira SA, Ferraz AR, Villar RC, Snitcovsky IM, Federico MH (2011) ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncol Rep 25:693–699PubMed

De Silva IU, McHugh PJ, Clingen PH, Hartley JA (2000) Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 20:7980–7990PubMedCrossRef

Doll CM, Prystajecky M, Eliasziw M, Klimowicz AC, Petrillo SK, Craighead PS, Hao D, Diaz R, Lees-Miller SP, Magliocco AM (2010) Low ERCC1 and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. Radiother Oncol 97:352–359PubMedCrossRef

Ferrigan L, Wallace WA (2004) Predicting non-small cell lung cancer expression of epidermal growth receptor and matrix metalloproteinase 9 from immunohistochemical staining of diagnostic biopsy samples. Eur J Cancer 40:1589–1592PubMedCrossRef

Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolau A, Karayannopoullou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, Aravantinos G, Markou K, Athanassiou E, Misailidou D, Kalogeras KT, Skarlos D (2009) MMP9 but not EGFR, MET, ERCC1, P16 and P-53 is associated with response to concomitant radiotherapy, Cetuximab and weekly cisplatin in patients with locally advanced head and neck cancer. J Oncol. doi:10.1155/2009/305908

Goyal S, Parikh RR (2010) Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys 76:679–684PubMedCrossRef

Gregoire V, Lefebvre J-L, Licitra L, Felip E (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl. 5):v184–v186PubMedCrossRef

Guo WF, Lin RX, Huang J, Zhou Z, Yang J, Guo GZ, Wang SQ (2005) Identification of differentially expressed genes contributing to radioresistance in lung cancer cells using microarray analysis. Radiat Res 164:27–35PubMedCrossRef

Hayes M, Lan C, Yan J, Xie Y, Gray T, Amirkhan RH, Dowell JE (2011) ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation. Anticancer Res 31:4135–4139PubMed

Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K (2008) ERCC1 expression as a prognostic marker in N2 (+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 113:1379–1386PubMedCrossRef

Jeong J, Hong S-J, Ju Y-J, Kim B-Y, Park M-J, Kim T-H, Park C-I, Choi K-Y, Cho M-H, Kim S-H, Lee H, Lee K-H (2006) Temporal cDNa microarray analysis of gene expression in human hepatocellular carcinoma upon radiation exposure. Oncol Rep 15:33–48PubMed

Johung KL, Rewari A, Wu H, Contessa J, Haffty B, Decker R (2010) Role of excision repair cross complementation 1 expression as a prognostic marker for response to radiotherapy in early stage laryngeal cancer. Proceeding of the 52nd annual ASTRo meeting. Int J Radiat Oncol Biol Phys 78(Suppl):abstr. 3000

Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong H-S, Son Y-I, Baek J-H, Park K (2008) ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 99:167–172PubMedCrossRef

Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality and prevalence across five continents. Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150PubMedCrossRef

Kim MK, Cho K-J, Kwon GY, Park S-I, Kim YH, Kim JH, Song H-Y, Shin JH, Jung HY, Lee GH, Choi KD, Kim S-B (2008) Patients with ERCC1 negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res 14:4225–4231PubMedCrossRef

Kirschner K, Melton DW (2010) Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 30:3223–3232PubMed

Lima LM, de Souza LR, da Silva TF, Pereira CS, Guimaraes AL, de Paula AM, de Carvalho Andrade H (2012) DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors. Histopathology 60:489–496PubMedCrossRef

Mehra R, Cai KQ, Zhu F, Weaver J, Nicolaou N, Cohen RB, Lango M, Ridge JA, Godwin AK, Burtness B (2010) Analysis of ERCC1 (excision repair cross complementing group 1) in squamous cell carcinoma of the head and neck (SCCHN) by quantitative immunohistochemistry (IHC) using FL297. J Clin Oncol 28 (15s, Suppl):abstr. 5539

Metzger R, Bollschweiler E, Hölscher AH, Warnecke-Eberz U (2010) ERCC1: impact in multimodality treatment of upper gastrointestinal cancer. Future Oncol 6:1735–1749PubMedCrossRef

Murray D, Rosenberg E (1996) The importance of the ERC1/ERCC4 [XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutat Res 364:217–226PubMedCrossRef

Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, de Wit J, Jaspers NGJ, Berna Beverloo H, Hoeijmakers JHJ, Kanaar R (2004) The structure-specific endonuclease ERCC1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24:5776–5787PubMedCrossRef

Nix P, Greenman J, Cawkwell L (2004) Expression of XRCC1 and ERCC1 proteins in radioresistant and radiosensitive laryngeal cancer. Cancer Ther 2:47–53

Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC (2006) DNA repair by ERCC1 in non-small cell lung cancer and cisplatin based adjuvant chemotherapy. N Engl J Med 355:983–991PubMedCrossRef

Reed E (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24:331–344PubMedCrossRef

Romero Q, Bendahl P-O, Klintman M, Loman N, Ingvar C, Ryden L, Rose C, Grabau D, Borquist S (2011) Ki67 proliferation in core biopsies versus surgical samples—amodel for neo-adjuvant breast cancer studies. BMC Cancer. doi:10.1186/1471-2407-11-341 PubMed

Sargent RG, Meservy JL, Perkins BD, Kilburn AE, Intody Z, Adair GM, Nairn RS, Wilson JH (2000) Role of the nucleotide excision repair gene ERCC1 in formation of recombination dependent rearrangements in mammalian cells. Nucleic Acids Res 28:3771–3778PubMedCrossRef

Scheil-Bertram S, Tylus-Schaaf P, du Bois A, Harter P, Oppitz M, Ewald-Riegler N, Fisseler-Eckhoff A (2010) Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high grade serous ovarian adenocarcinoma. Gynecol Oncol 119:325–331PubMedCrossRef

Shirota Y, Stoehlmacher J, Brabender J, Xiang YP, Uetake H, Danenberg KD, Groshens S, Tsao-Wei DD, Danenberg P, Lenz HJ (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298–4304PubMed

Simon GR, Sharma S, Cantor A, Smith P, Bepler G (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127:978–983PubMedCrossRef

Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S, Taranchon E, Mountzios G, Validire P, Domont J, Girard P, Grunenwald D, Le Chevalier T, Soria J-C (2007) Immunohistochemical expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 18:1043–1050PubMedCrossRef

Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ (1996) Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 35:10004–10013PubMedCrossRef

Titel: Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy
verfasst von: Vesna Bišof
Antonija Jakovčević
Sven Seiwerth
Zoran Rakušić
Slavko Gašparov
Publikationsdatum: 01.02.2013
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 2/2013
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-012-1318-8

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval

A nine-gene signature predicting clinical outcome in cutaneous melanoma

A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy

New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma

KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines

Prognostic value and differences of the sixth and seventh editions of the UICC/AJCC staging systems in nasopharyngeal carcinoma

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie